All News

A summary of the key impacts new law, California Consumer Privacy Act (CCPA), will have on business practices related to data flow in specialty pharma, and more.

A list of eight points to help pharmaceutical executives focus on the role they need to play to build and maintain robust long-term partnerships.

AMCP Format Version 4.1 provides manufacturers with additional guidance to communicate evidence about potential new products or new uses to payers in a compliant fashion.

test test test

In China’s new reform-driven and fast-moving environment for healthcare innovation, intense market pressures and fierce competition will ultimately push all stakeholders to evolve their strategies-or face extinction.

The industry faces a problem of medical education and communication in regards to vaccinations.

A look at drug pricing and patents and the role for patents and how they are under attack.

With so many different rationales for drug pricing and “value” continuing to feed the debate, the market access function in healthcare must clearly tackle these issues-but at what cost to the patient?

FDA has an official new leader, following a Senate vote to confirm Stephen Hahn as the agency’s next commissioner.

With an increase in digital technology being utilized as a strategic differentiator and business enabler in pharma, where is talent coming from?

A new assessment shows year-over-year improvements on meeting DSCSA serialization requirements, which indicate the industry is making steady progress.

Gauging physician awareness of nucleic acid-based therapies.

Click the title above to open the Pharmaceutical Executive December 2019 issue in an interactive PDF format.

More than two years since the devastation inflicted by Hurricane Maria, Puerto Rico’s supply of medical products has remained largely uninterrupted, debunking common misconceptions at the time and maintaining the island’s standing as one of the most attractive life sciences manufacturing hubs.

A look at the systemic problems resulting from the overlap of MDRP and 340B.

Takeaways from the Healthcare Businesswomen’s Association's 2019 Annual Conference.

2020 PE Pipeline Report

A look at how to develop a generic drug and the resources FDA supplies to Abbreviated New Drug Application applications.

A review of the current use of real-world data and evidence in HTA and payer appraisals, its potential role in lifecycle management, and how the early dialogue provided by Integrated Scientific Advice engagement can be used as a key tool in the planning and generation of RWE.